Bill > S2027

This bill aims to modernize how prescription drug information is communicated by allowing pharmaceutical manufacturers to provide prescribing information electronically instead of solely through paper documentation. Specifically, the bill amends the Federal Food, Drug, and Cosmetic Act to permit drug manufacturers to make prescribing information available exclusively through digital means, with two important caveats: manufacturers must give healthcare professionals the option to continue receiving paper copies, and they must promptly provide paper labeling upon request at no additional cost. The Secretary of Health and Human Services is required to issue final regulations within one year of the Act's enactment, with instructions on how healthcare professionals can obtain paper copies if desired. The regulations must be designed to minimize economic impacts on prescribers and dispensers. Additionally, the bill mandates a public workshop within two years to discuss further improvements to prescribing information's format, accessibility, and usability. The digital communication provision will take effect either two years after the Act's enactment or on the effective date of the final regulations, whichever comes first. This bill represents a step toward modernizing medical information distribution while preserving healthcare professionals' ability to access information in their preferred format.

Health and Social Services

https://www.congress.gov/bill/119th-congress/senate-bill/2027/all-info